Delphine Darbord

Delphine Darbord

Auto-generated profile, based on publicly available information

Delphine Darbord

Pathology Department and

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Blood
Verified
Journal Article
Closed access
PDF file
AMAdèle De Masson
Adèle De Masson
DDDelphine Darbord
Delphine Darbord
GDGabor Dobos
Gabor Dobos
MBMarie Boisson
Marie Boisson
MRMarie Roelens
Marie Roelens
Maxime BattistellaMaxime Battistella
Maxime Battistella
Cutaneous T-cell lymphomas (CTCLs) are rare malignancies involving primarily the skin. Responses to treatment are usually short-lived in advanced CTCL. The determinants of long-term CTCL control are unclear. Mogamulizumab, an anti-human CCR4 antibody that acts by antibody-dependent cell cytotoxicity against CCR4+ CTCL tumor cells and peripheral memory blood regulatory T cells, has been associated with long-lasting remissions and immune adverse events. Here, we reported skin rashes in 32% of 44 patients with CTCL treated with mogamulizumab, associated with significantly higher overall survival (hazard ratio, 0.16; 0.04-0.73; P = .01). Rash occurred in patients with Sézary syndrome and was associated with longer time to progression. These rashes were characterized by a CD163+ granulomatous and/or CD8+ lichenoid skin infiltrate. High-throughput sequencing analysis of T-cell receptor β genes in skin and blood flow cytometry confirmed the depletion of CTCL tumor cells, as well as the recruitment of new reactive T-cell clones in skin at the time of skin rash. CXCL9 and CXCL11, two macrophage-derived chemokines that recruit CXCR3+ T cells to skin, were overexpressed in skin rashes. A higher frequency of TIGIT+ and PD1+ exhausted reactive blood T cells was observed at baseline in patients with rash, and this frequency decreased with mogamulizumab treatment. These data are consistent with mogamulizumab-induced long-term immune CTCL control by activation of the macrophage and T-cell responses in patients with rash.

19 November 2021 in Annales de Dermatologie et de Vénéréologie - FMC
Verified
Journal Article
Closed access
SBSimar Berro
Simar Berro
ACAlbane Calas
Albane Calas
PSPierre Sohier
Pierre Sohier
DDDelphine Darbord
Delphine Darbord
SASelim Aractingi
Selim Aractingi
Nicolas DupinNicolas Dupin
Nicolas Dupin